<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04450030</url>
  </required_header>
  <id_info>
    <org_study_id>INCIDENTMS2018</org_study_id>
    <nct_id>NCT04450030</nct_id>
  </id_info>
  <brief_title>Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis</brief_title>
  <acronym>INCIDENT-MS</acronym>
  <official_title>Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis - Assessment of Mechanism of Action</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of acute relapsing multiple sclerosis (MS) has remained largely unaltered within
      past years. However, evidence defining the exact role of apheresis treatment in the
      therapeutic sequence is still incomplete. INCIDENT-MS evaluates the mechanism of action of
      immunoadsorption compared to escalated methyl prednisolone treatment in steroid-refractory MS
      relapses and thereby will help to identify predictive markers for optimal treatment choice
      and will generate further insights into the pathophysiology of MS relapses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expanded disability status scale (EDSS)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Improvement of disability compared to peak relapse EDSS following escalation treatment compared to peark relapse values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual-evoked potentials (VEP; P100-latency)</measure>
    <time_frame>2 weeks; 6 to 8 weeks</time_frame>
    <description>Evolution of VEP P100-latency compared to peak relapse values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>somatosensory-evoked potentials (SEP; Medianus and Tibialis; N20-, P40-latency)</measure>
    <time_frame>2 weeks; 6 to 8 weeks</time_frame>
    <description>Evolution of SEP N20-/P40-latency compared to peak relapse values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>best-corrected visual acuity (bcVA)</measure>
    <time_frame>2 weeks; 6 to 8 weeks</time_frame>
    <description>Evolution of bcVA compared to peak relapse values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded disability status scale (EDSS)</measure>
    <time_frame>6 to 8 weeks</time_frame>
    <description>Confirmation of improvement of disability compared to primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple scleroris functional compositie (MSFC)</measure>
    <time_frame>2 weeks, 6 to 8 weeks</time_frame>
    <description>Development of MSFC z-score compared to peak relapse values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short form-36 questionaire (SF-36)</measure>
    <time_frame>6 to 8 weeks</time_frame>
    <description>Development of quality-of-life compared to peak relapse values</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Intravenous methyl prednisolone</arm_group_label>
    <description>Patients receiving an additional course of intravenous methyl prednisolone for treatment of a steroid-refractory MS relapse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunoadsorption</arm_group_label>
    <description>Patients receiving 6 courses of immunadsorption treatment for treatment of a steroid-refractory MS relapse</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl Prednisolonate</intervention_name>
    <description>2000mg intravenous methyl prednisolone per day for five consecutive days</description>
    <arm_group_label>Intravenous methyl prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immunoadsorption</intervention_name>
    <description>6 courses of tryptophane-based immunoadsorption within up to 12 days</description>
    <arm_group_label>Immunoadsorption</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute relapsing multiple sclerosis that were refractory to a first course of
        intravenous methyl prednisolone (1000mg per day for three to five consecutive days)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  Diagnosis of relapsing-remitting multiple sclerosis according to 2017 revised
             McDonald-criteria

          -  Incomplete remission of relapse symptoms following initiation treatment with 1000mg/d
             intravenous methyl prednisolone

          -  Absence of fever or clinically apparent signs of infection

        Exclusion Criteria:

          -  Baseline EDSS score &gt;6.5 points

          -  Previous administration of less than 3x1000mg or more than 5x1000mg IVMPS for
             initiation treatment

          -  Known pregnancy or rejection to perform a pregnancy test (female patients only)

          -  Immunosuppressive treatment for conditions other than multiple sclerosis

          -  Ongoing neoplastic disorder or past neoplastic disorder within previous five years

          -  Known or newly diagnosed HIV-, HBV- or HCV-infection

          -  Regular intake of ACE inhibitor drugs

          -  Known bleeding disorders (including laboratory abnormalities such as: (I) platelet
             count&lt;50.000/ÂµL; (II) international normalized ratio&gt;1.5, (III) activated prothrombin
             time&gt;50s) or intake of oral anticoagulant drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven G Meuth, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Muenster, Department of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steffen Pfeuffer, Dr</last_name>
    <phone>00492518344463</phone>
    <email>steffen.pfeuffer@ukmuenster.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology with Institute of Translational Neurology, University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <state>Northrhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Pfeuffer, Dr.</last_name>
      <phone>002518344463</phone>
      <email>steffen.pfeuffer@ukmuenster.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>June 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunoadsorption</keyword>
  <keyword>intravenous methyl prednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

